T-cell Therapy Market Overview:
According to IMARC Group latest report titled “T-cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on T-cell therapy market trends. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global T-cell therapy market is expected to exhibit a CAGR of 16.9% during 2022-2027.
T-cell therapy is an immunotherapy approach wherein the immune cells from the body of the patient are utilized to treat cancer. It comprises of a transmembrane domain, an antigen-binding ectodomain, intracellular endodomain, and Immune Receptor Tyrosine-Based Activation Motifs (ITAMs). T-cell therapy can be of several types, such as CAR T-cells, Tumor-Infiltrating Lymphocytes (TIL), and T-cell Receptors (TCRs). It involves collecting T-cells via apheresis for re-engineering them in a laboratory. The re-engineered cells from T-cell therapy processes are multiplied and then infused into the body to kill cancer cells. Consequently, they find widespread application across numerous healthcare facilities, including hospitals and cancer treatment centers.
Request to Get the Free Sample Report: https://www.imarcgroup.com/t-cell-therapy-market/requestsample
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
The rising incidences of cancer and the growing consumption of unhealthy foods and tobacco products are primarily driving the T-cell therapy market. Furthermore, the elevating prevalence of bone marrow and blood-forming tissue ailments is further positively influencing the market growth. Besides this, inflating utilization of AC-T chemotherapy processes to treat children suffering from Acute Lymphoblastic Leukemia (ALL) and adults with advanced lymphomas is acting as another significant growth-inducing factor. Moreover, the expanding investments in research and development (R&D) activities undertaken by the key pharmaceutical companies are anticipated to bolster the T-cell therapy market in the coming years.
Competitive Landscape with Key players:
The report has also analysed the competitive landscape of the market with some of the key players being.
- Amgen Inc.
- Aurora Biopharma Inc.
- bluebird bio Inc
- Bristol-Myers Squibb Company
- Fate Therapeutics
- Gilead Sciences Inc.
- Merck KGaA
- Mustang Bio Inc.
- Novartis AG
- Pfizer Inc.
- Sorrento Therapeutics Inc.
- TCR2 Therapeutics
T-cell Therapy Market Segmentation:
Our report has categorized the market based on region, modality, therapy type and indication.
- CAR T-cell based
- T Cell Receptor (TCR) based
- Tumor Infiltrating Lymphocytes (TIL) based
- Hematologic Malignancies
- Solid Tumors
- Brain and Central Nervous System
- Liver Cancer
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
We are updating our reports, If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Competitive landscape, etc. Click request free sample report, the report will be delivered to you in PDF format via email within 24 to 48 hours after the payment confirmation.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800